Standout Papers

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis 2023 2026 2024145
  1. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis (2023)
    Geert D’Haens, Marla C. Dubinsky et al. New England Journal of Medicine

Immediate Impact

42 standout
Sub-graph 1 of 20

Citing Papers

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
2025 Standout
Artificial intelligence to revolutionize IBD clinical trials: a comprehensive review
2025 Standout
4 intermediate papers

Works of Joe Milata being referenced

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2023 Standout
Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial
2011

Author Peers

Author Last Decade Papers Cites
Joe Milata 129 164 12 61 10 243
Sebastian Schroepf 43 72 17 52 10 154
Josselin Rigaill 42 38 12 17 16 149
Antonio López-Sanromán 75 88 11 56 12 205
Ana Vieira 150 215 18 90 11 289
Bénédicte De Vroey 127 125 2 100 16 298
Rebecca Rogier 47 58 6 73 9 286
Sara A. Murray 84 51 14 86 8 274
Antonella Contaldo 120 107 27 26 17 272
Mireia Peñalva 169 216 27 50 15 295
Peter Asquith 119 80 15 42 9 252

All Works

Loading papers...

Rankless by CCL
2026